Fasoracetam (NS-105 / NFC-1 / AEVI-001 / NB-001 / SYN-001): The mGluR Biomarker Story Behind the Only Racetam in an Active FDA Orphan Drug Program
Among the racetams that survived the 1990s nootropic consolidation, only one has cleared the FDA Orphan Drug gate and the FDA Rare Pediatric Disease gate in 2024–2026, and only one has a placebo-controlled adolescent study in Nature Communications with a three-arm genetic stratification. Fasoracetam's 38-year path through Nippon Shinyaku, Medgenics, Aevi Genomic Medicine, Cerecor / Avalo Therapeutics, Nobias Therapeutics, and Synaptiq Therapeutics defines a clinical development archetype that no other piracetam-family compound approaches.
At a Glance
Contents
- The Biomarker Paradox: A "Failed" Phase 3 Becomes the Only Active Racetam Orphan Program
- From Vascular Dementia to Genomic ADHD: The Six-Sponsor Lineage of NS-105 → SYN-001
- The Phase 1b/2 Anchor: Elia 2018 in Nature Communications 9:4
- Why ASCEND (2018–2019) Failed and What the Failure Told
- Rebound to 22q11.2 Deletion Syndrome: Nobias → Synaptiq
- Mechanism of Action: The Only Racetam with Validated mGluR Binding
- Solid-State Critical: 57 °C Melting Point and Hydrate Form I
- Global Regulatory Status: Five Cross-Reference Designs, Four Schedules
- Research-Grade Sourcing: Enantiomer Purity and Starting Material
- Packaging and Lead Time: 10 G, 100 G, 1 KG, 10 KG, 25 KG
- Frequently Asked Questions
- Conclusion
1. The Biomarker Paradox: A "Failed" Phase 3 Becomes the Only Active Racetam Orphan Program
Fasoracetam is the only member of the racetam family to have travelled from a Japanese Phase 3 vascular dementia programme in the 1990s to an active FDA Orphan Drug designation in 2024 and a Rare Pediatric Disease Designation in 2026, while also being the only racetam whose placebo-controlled adolescent study landed in Nature Communications. The molecule's 38-year trajectory through six corporate sponsors — Nippon Shinyaku, neuroFix Therapeutics, Medgenics (later Aevi Genomic Medicine), Cerecor (later Avalo Therapeutics), Nobias Therapeutics, and Synaptiq Therapeutics — defines a development archetype that no other piracetam-family compound approaches.
The paradox sits at the centre of the story. The 2019 ASCEND trial of AEVI-001 (NCT02867542 Part A; NCT03609619 Part B) failed to meet its primary ADHD-RS endpoint in both the mGluR copy-number-variant-positive and the copy-number-variant-negative arms. Five years later, the same molecule carries FDA Orphan Drug status for 22q11.2 deletion syndrome (DiGeorge syndrome), a population whose glutamatergic network disruption is precisely the pathology that AEVI-001 was retuned to address. The "failure" of 2019 and the "approval-track" status of 2026 are not contradictions; they are two readings of an identical biomarker hypothesis applied to two genetically distinct populations.
2. From Vascular Dementia to Genomic ADHD: The Six-Sponsor Lineage of NS-105 → SYN-001
Five sponsor companies, six development codes, and one continuous investigator (Hakon Hakonarson, M.D., Ph.D., Director of the Center for Applied Genomics at Children's Hospital of Philadelphia) link the 1990s Japanese programme to the 2026 Synaptiq Phase 2b in 22q11.2 deletion syndrome. The lineage is the single most cited factual record in fasoracetam literature and the source of frequent confusion in sourcing enquiries — five distinct catalogue codes refer to one molecule.
| Code | Sponsor | Period | Indication pursued | Outcome |
|---|---|---|---|---|
| NS-105 | Nippon Shinyaku (Kyoto, JP) | c. 1988 – 1997 | Vascular dementia | Phase 3 failed efficacy; compound returned to originator |
| NFC-1 | neuroFix Therapeutics → Medgenics (acquired 2015) | 2014 – 2016 | mGluR-mutated adolescent ADHD | Indication acquired; code retired on corporate rename |
| AEVI-001 | Aevi Genomic Medicine (renamed from Medgenics 2016; NASDAQ:GNMX) | 2016 – 2019 | mGluR-mutated ADHD + 22q11.2 DS exploratory | SAGA trend positive; ASCEND Part A and Part B failed primary endpoint Jan 2019 |
| (unbranded at Aevi) | Cerecor → Avalo Therapeutics | 2019 – 2020 | Programme shelved | Rights transferred out of public disclosure |
| NB-001 | Nobias Therapeutics | 2021 – 2026 | 22q11.2 deletion syndrome neuropsychiatric symptoms | Phase 2 met safety primary; efficacy trend in CGI-I p=0.07; FDA Orphan Drug Oct 2024 |
| SYN-001 | Synaptiq Therapeutics (Reykjavík, IS) | 23 Jul 2026 – present | 22q11.2 DS Phase 2b planned | FDA Rare Pediatric Disease Designation 04 Aug 2026 |
The codes translate as: NS-105 = Nippon Shinyaku compound 105; NFC-1 = NeuroFix Compound 1; AEVI-001 = Aevi internal candidate 001; NB-001 = Nobias candidate 001; SYN-001 = Synaptiq candidate 001. A sixth code, MDGN-001, appears in some regulatory filings during the 2014–2015 transition window and refers to the same substance under the Medgenics codename.
3. The Phase 1b/2 Anchor: Elia 2018 in Nature Communications 9:4
The single most-quoted primary record in the fasoracetam literature is Elia J. et al., "Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling," Nature Communications 9:4 (16 January 2018), DOI 10.1038/s41467-017-02244-2, PMID 29339723, registered at ClinicalTrials.gov as NCT02286817. The five-week, open-label, single-blind, placebo-controlled study enrolled 30 adolescents aged 12–17 carrying mutations in mGluR network genes.
| Endpoint | Baseline (week 1, placebo) | End of treatment (week 5) | P-value |
|---|---|---|---|
| CGI-I (Clinical Global Impressions – Improvement) | 3.79 | 2.33 | < 0.001 |
| CGI-S (Severity) | 4.83 | 3.86 | < 0.001 |
| Parental Vanderbilt (Tier 1 mGluR variants) | — | Significant improvement | < 0.035 |
Dose escalation began with single-dose pharmacokinetic profiling from 50 mg to 800 mg, followed by a single-blind placebo at week 1 and symptom-driven dose advancement up to 400 mg twice daily for four weeks. The trial's mutation-status double-blinding was a defining design choice: investigators knew the genotype stratification but did not know which arm each subject's symptoms would be analysed against, while the placebo comparator at week 1 served as an internal baseline anchor for each subject.
The publication's secondary metrics — BRIEF (Behaviour Rating Inventory of Executive Function) global scores and Vanderbilt inattention and hyperactivity subscales — favoured the Tier 1 (highest-priority mGluR network variant) subgroup, but the absence of a randomised placebo arm at week 5 means the trial sits within the Phase 1b/2 evidence tier rather than the confirmatory Phase 3 tier. Subsequent Aevi Genomic Medicine press releases explicitly cite the Elia 2018 cohort as the "proof-of-concept" anchor for the SAGA and ASCEND programmes.
4. Why ASCEND (2018–2019) Failed and What the Failure Told
On 2 January 2019 Aevi Genomic Medicine announced top-line results from the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled study of AEVI-001 in children aged 6–17 with ADHD, run in two parts: Part A in subjects with an mGluR copy-number variant (NCT02867542) and Part B in subjects without (NCT03609619). Both parts failed to achieve statistical significance on the primary endpoint of reduction in ADHD-RS total score after six weeks of treatment with AEVI-001 at 100–400 mg BID.
| Trial arm | Population | Dose | Duration | Primary endpoint | Outcome |
|---|---|---|---|---|---|
| ASCEND Part A | Children 6–17 with mGluR CNV | 100–400 mg BID | 6 weeks | ADHD-RS reduction | Did not achieve significance |
| ASCEND Part B | Children 6–17 without mGluR CNV | 100–400 mg BID | 6 weeks | ADHD-RS reduction | Did not achieve significance |
| SAGA (predecessor) | Adolescents 12–17 with mGluR mutation | 100–400 mg BID | 5 weeks | ADHD-RS total (missed); inattention p=0.0515 | Did not meet primary; strong subscale and response-rate signal at 400 mg BID |
The ASCEND result is not the simple negative that the headline conveys. The SAGA trial (March 2017 top-line) had shown a 70 % ADHD-RS response rate (p=0.0067 vs placebo) and a 57 % CGI-I response rate (p=0.0155 vs placebo) at the 400 mg BID dose, with the strongest signal in the highest-dose subgroup. The ASCEND trial widened the age range downward to six years and the dose range to 100–400 mg BID — a protocol design that diluted the high-dose signal and broadened the genetic heterogeneity within the CNV-positive arm.
The clinical signal that ASCEND preserved was tolerability: across 100–400 mg BID for six weeks in children aged 6–17, AEVI-001 showed a safety profile indistinguishable from placebo. Aevi Genomic Medicine was subsequently acquired by Cerecor (later renamed Avalo Therapeutics) and the ADHD indication was deprioritised. The rights to the compound later surfaced at Nobias Therapeutics, where the indication pivot to 22q11.2 deletion syndrome took shape.
5. Rebound to 22q11.2 Deletion Syndrome: Nobias → Synaptiq
22q11.2 deletion syndrome (DiGeorge syndrome, velocardiofacial syndrome) is a congenital disorder in which a hemizygous microdeletion on chromosome 22 disrupts roughly 50 genes, producing a high prevalence of anxiety, ADHD-like symptoms, autism-related features, and other neuropsychiatric manifestations. Glutamatergic network dysfunction is a documented feature of the syndrome, providing a direct mechanistic bridge to AEVI-001's mGluR-targeting profile.
Nobias Therapeutics ran a Phase 2 randomised, placebo-controlled crossover trial of NB-001 (fasoracetam monohydrate) in children and adolescents aged 6–17 with 22q11.2 deletion syndrome (NCT05290493). The trial enrolled 37 participants and met its primary safety endpoint. Top-line efficacy signals were presented at the 52nd Child Neurology Society Annual Meeting in October 2023 and published in May 2025 in a peer-reviewed supplement to Biological Psychiatry.
| Endpoint (Phase 2 NB-001, n=37, ages 6–17) | NB-001 | Placebo | Delta / signal |
|---|---|---|---|
| CGI-I least-squares mean | 3.34 | 3.69 | −0.36, p=0.07 |
| Responder rate (multiple thresholds) | 1.4–1.7× placebo | — | Trend, not powered for significance |
| Adverse events | Fatigue 9 %, nasopharyngitis 9 % | Comparable | No SAE attributed to study drug |
On the strength of the Phase 2 safety primary endpoint and the CGI-I trend, the FDA granted Orphan Drug designation to fasoracetam monohydrate for the treatment of 22q11.2 deletion syndrome in October 2024. In June 2025 Nobias announced preliminary alignment with the FDA on registrational endpoints for a potential Phase 3 programme, and on 23 July 2026 Synaptiq Therapeutics (Reykjavík, Iceland) acquired substantially all Nobias assets, renaming NB-001 to SYN-001. Eleven days later, on 4 August 2026, the FDA granted Rare Pediatric Disease Designation (RPDD) to Synaptiq's fasoracetam monohydrate for DiGeorge syndrome — the second FDA designation the molecule now holds, and a trigger for a Priority Review Voucher upon eventual approval.
6. Mechanism of Action: The Only Racetam with Validated mGluR Binding
Fasoracetam is the only racetam-class compound with documented affinity at a specific G-protein-coupled receptor family. Three mechanistic pillars are referenced across the primary literature:
| Target | Receptor class | Effect documented | Primary source |
|---|---|---|---|
| mGluR Group III | Gi/o-coupled (mGluR4, mGluR6, mGluR7, mGluR8) | Positive allosteric modulation / agonist activity | Ofoegbu et al. preclinical studies; Aevi preclinical package |
| GABAB | Gi/o-coupled heterodimer (GB1/GB2) | Antagonism or partial negative modulation | Synapse / AdisInsight mechanism summary; Aevi IND documentation |
| Choline uptake (HAChU pathway) | High-affinity choline transporter (CHT1) | Enhancement of choline uptake in rodent synaptosomes | Nippon Shinyaku preclinical; cited in Elia 2018 supplementary methods |
mGluR Group III receptors are predominantly presynaptic autoreceptors that inhibit glutamate release when activated — the mechanistic rationale for fasoracetam's hypothesised "glutamate rebalancing" effect in mGluR-network-disrupted populations is that enhanced Group III activity clamps down on pathologically elevated glutamate tone. GABAB antagonism is mechanistically adjacent to the choline uptake enhancement documented in the original Nippon Shinyaku vascular dementia package, providing a bridge to the cognitive-endpoint rationale that the original Phase 3 in vascular dementia was built on.
7. Solid-State Critical: 57 °C Melting Point and Hydrate Form I
Three crystalline forms of fasoracetam have been indexed in the solid-state literature: two hydrates and one anhydrate. Under ambient conditions the monohydrate form I is the most thermodynamically stable. The melting point of monohydrate form I — 57 °C — is the most consequential physical property in the molecule's commercial handling profile.
A 57 °C melting point sits below the interior temperature of an unventilated delivery vehicle in summer. A parcel that traverses a hot distribution lane can therefore arrive as a resolidified melt. The compound does not decompose by melting-and-resolidifying, and it will still assay as chemically pure by HPLC, NMR and LC-MS. What changes is the polymorphic form: a single resolidification event can convert monohydrate form I into a mixture of form I, form II, and the anhydrate, with water content drifting away from the 8.4 % monohydrate stoichiometry that the molecular weight calculation assumes.
| Solid form | Water content | Melting / transition | Stability under ambient conditions |
|---|---|---|---|
| Monohydrate form I | ~8.4 % w/w | mp 57 °C | Thermodynamically most stable |
| Monohydrate form II | ~8.4 % w/w | Distinct DSC trace | Metastable |
| Anhydrate | < 0.5 % w/w | mp onset 92.6 °C | Accessible via dehydration of form I |
The 8.4 % water stoichiometry propagates directly into any concentration derived by mass balance. A 100 mg sample weighed as monohydrate form I contains 91.6 mg of anhydrous fasoracetam and 8.4 mg of water; the same mass of anhydrate contains 100 mg of anhydrous compound. Karl Fischer titration is the analytical method that resolves the mass balance, and a certificate of analysis that does not report water content is incomplete for any quantitative protocol downstream of simple identity confirmation.
8. Global Regulatory Status: Five Cross-Reference Designs, Four Schedules
The regulatory status of fasoracetam is fragmented across jurisdictions in a way that compounds the molecule's clinical-trial history. No central marketing authorisation exists; the FDA designations are indication-specific and tied to 22q11.2 deletion syndrome, not to general ADHD or cognitive-enhancement use.
| Jurisdiction | Status | Schedule / designation | Implication for research supply |
|---|---|---|---|
| United States (FDA) | Not FDA-approved for any indication; research chemical | Orphan Drug for 22q11.2 DS (Oct 2024); RPDD for DiGeorge syndrome (Aug 2026) | Investigational use only; sale as a supplement or therapeutic product is prohibited |
| European Union (EMA) | Not authorised as a medicinal product | — | Research use permitted; medicinal marketing prohibited |
| United Kingdom (MHRA) | No medicinal authorisation; unscheduled under Misuse of Drugs Act | — | Research use permitted without controlled-drug restrictions |
| Australia (TGA) | Schedule 4 (Prescription Only Medicine) since February 2020 | S4 | Supply restricted to pharmacy on prescription; research supply is via analytical-reagent framework |
| Japan (PMDA) | Not approved for marketing or clinical use, despite development origin | — | No domestic sponsor; research import via analytical-reagent licence |
| Canada (Health Canada) | Not listed under Controlled Drugs and Substances Act | — | Research use permitted |
HS classification for customs declarations in most jurisdictions falls under HS 2933.79 (other lactams) or, where the pyrrolidin-2-one ring is treated as a heterocyclic lactam, HS 2933.71. The classification is not harmonised across customs authorities and is sensitive to the declared use (research reagent vs pharmaceutical API). The U.S. HTSUS equivalent falls under 2933.79.90; the EU/UK CN code is 2933 79 00; the Chinese customs code is 2933790000.
9. Research-Grade Sourcing: Enantiomer Purity and Starting Material
Fasoracetam is supplied as a single (5R) enantiomer. The InChIKey block ends MRVPVSSYSA-N rather than UHFFFAOYSA-N — the second InChIKey layer encodes stereochemistry, and the defined block confirms a single enantiomer rather than a racemate. This is the simplest identity test for distinguishing reference-grade material from racemic pyroglutamate-derived material.
Two synthetic routes dominate the published and patent literature:
- D-pyroglutamic acid condensation with piperidine. The classical Nippon Shinyaku route. Starting material is D-pyroglutamic acid (CAS 4042-36-8), condensed with piperidine under amide-coupling conditions (DCC / acetonitrile, or p-toluenesulfonic acid / toluene followed by acetonitrile addition at room temperature).
- L-pyroglutamic acid resolution and inversion. Less common; produces the same enantiomer via inversion chemistry. Used by some Indian and Chinese manufacturers as a cost optimisation route.
Counterfeit and substitution patterns documented in 2024–2026 sourcing enquiries include: (a) racemate sold as single enantiomer; (b) the related 5-oxo-L-proline piperidinamide (the inactive enantiomer) sold as fasoracetam; (c) NS-105 catalogue numbers pointing to material with no chiral data on the certificate of analysis; (d) material labelled as monohydrate with Karl Fischer water content inconsistent with the 8.4 % monohydrate stoichiometry.
10. Packaging and Lead Time: 10 G, 100 G, 1 KG, 10 KG, 25 KG
Fasoracetam is supplied to research-grade specifications in five stock pack sizes across the principal commercial envelope, each addressing a distinct downstream use case.
| Pack size | Typical use case | Container | Lead time, ex-stock |
|---|---|---|---|
| 10 G | Reference standard, chiral-method qualification, single-instrument analytical method development | Amber glass vial, PTFE-lined cap, silica desiccant sachet | 3–7 business days |
| 100 G | Method validation campaigns, multi-batch comparator work, in vitro pharmacology panels | Amber glass jar, PTFE-lined cap, factory-sealed foil pouch | 3–7 business days |
| 1 KG | Pharmacokinetic study supply, animal model formulation batches, clinical-trial reference material | Amber glass jar in aluminium-foil overpack, twin desiccant sachets | 7–14 business days |
| 10 KG | Multi-site clinical research programmes, formulation development, batch-release validation | Fibre drum with HDPE inner liner, double-foil barrier, desiccant pack | 14–28 business days |
| 25 KG | Industrial research supply, large-cohort clinical research, regional redistribution | Fibre drum with HDPE liner, double-foil barrier, nitrogen-purged headspace | 21–35 business days |
Storage at receipt: sealed with desiccant, at 2–8 °C for medium-term storage or −20 °C for long-term archival. Temperature cycling between warm and cold should be avoided because repeated water uptake and loss can convert between hydrate forms. For quantitative protocols that rely on the monohydrate stoichiometry, Karl Fischer titration at receipt is the standard reconciliation step.
11. Frequently Asked Questions
What makes fasoracetam different from every other racetam?
Fasoracetam is the only racetam-class compound with documented affinity at a specific G-protein-coupled receptor family (mGluR Group III) and the only one to have entered the FDA Orphan Drug and Rare Pediatric Disease designation tracks. Other racetams — piracetam, aniracetam, oxiracetam, phenylpiracetam, coluracetam — share the 2-oxopyrrolidine (pyrrolidone) core but lack a defined receptor-binding profile at the same pharmacological resolution.
Why did the ASCEND Phase 2 trial fail when the Elia 2018 Nature Communications trial showed a P<0.001 signal?
The Elia 2018 trial enrolled 30 adolescents aged 12–17 with confirmed mGluR network mutations and used a single-blind placebo week-1 anchor. ASCEND widened the age range to 6–17 years, lowered the dose floor to 100 mg BID, and ran a six-week placebo-controlled design in both CNV-positive (Part A) and CNV-negative (Part B) arms. The protocol design diluted the high-dose signal in the CNV-positive arm and the placebo-controlled design removed the within-subject baseline that had anchored the Elia 2018 analysis. The failure is interpreted as a protocol-design outcome rather than a molecule-mechanism outcome.
Is fasoracetam FDA-approved for ADHD?
No. Fasoracetam is not FDA-approved for any indication as of September 2026. The FDA Orphan Drug designation (October 2024) and Rare Pediatric Disease Designation (August 2026) cover 22q11.2 deletion syndrome (DiGeorge syndrome), not ADHD.
What does the 22q11.2 deletion syndrome orphan drug designation actually do?
The Orphan Drug designation provides seven years of US market exclusivity upon eventual approval, tax credits for clinical trial expenses, waiver of FDA user fees, and access to FDA expedited review pathways. The Rare Pediatric Disease Designation provides a Priority Review Voucher (PRV) upon approval that can be sold or redeemed for priority review of a subsequent application. Both designations are tied to the 22q11.2 deletion syndrome indication only and do not extend to ADHD, cognitive enhancement, or other indications.
Which development code is currently active?
SYN-001 is the current code following the 23 July 2026 acquisition of the Nobias Therapeutics fasoracetam programme by Synaptiq Therapeutics. NB-001, AEVI-001, NFC-1, and NS-105 refer to the same molecule under prior sponsors but are not interchangeable in catalogue specifications.
Is fasoracetam safe to ship across hot transit lanes?
The 57 °C melting point of monohydrate form I is the primary constraint. Shipments crossing equatorial or subtropical transit lanes require climate-controlled freight, sealed containers with desiccant, and inspection on receipt for fused, glassy, or flowed-and-reset material. A melted-and-resolidified lot still assays as chemically pure by HPLC and LC-MS but its polymorphic form and Karl Fischer water content may have changed.
How does a buyer distinguish single-enantiomer fasoracetam from racemic material?
The InChIKey block ending MRVPVSSYSA-N (single (5R)) versus UHFFFAOYSA-N (racemate) is the cleanest identity test. Chiral HPLC against a single-enantiomer reference standard and polarimetry are the orthogonal confirmatory methods. Material without chiral data on the certificate of analysis should be regarded as racemate-by-default for research use.
Is fasoracetam a controlled substance in the United States?
No. Fasoracetam is not scheduled under the DEA Schedules I–V and is not on any state-level controlled-substance list as of September 2026. It is sold as a research chemical for laboratory use and is not approved for human consumption or medical treatment in the United States.
What is the regulatory status in Australia, the UK, and the EU?
Australia: Schedule 4 (Prescription Only Medicine) since February 2020. United Kingdom: not scheduled under the Misuse of Drugs Act but not authorised as a medicinal product by the MHRA; research use permitted. European Union: not authorised as a medicinal product by the EMA; research use permitted without centralised medicinal marketing restrictions.
Why does the molecule melt at 57 °C if other racetams melt much higher?
The 57 °C melting point reflects the monohydrate form I's specific crystal-packing and hydrogen-bonding geometry, not a general property of the pyrrolidinone family. Piracetam's melting point is around 152 °C and aniracetam's is around 121 °C. The hydrate water molecules disrupt the tighter crystal packing that anhydrous racetams achieve.
Which clinical trials used the highest published dose?
The Elia 2018 trial pharmacokinetic profiling ranged from 50 mg to 800 mg as a single dose, with repeat dosing up to 400 mg BID. The ASCEND trial dosed at 100–400 mg BID for six weeks. The Nobias Phase 2 in 22q11.2 deletion syndrome used paediatric weight-adjusted dosing within a comparable absolute range. The 800 mg single-dose ceiling was set by tolerability rather than by saturation of exposure in the Elia 2018 PK analysis.
Why is fasoracetam a research chemical and not a supplement?
Fasoracetam has no marketing authorisation in the United States, the European Union, the United Kingdom, Japan, Australia, or Canada. Sale as a dietary supplement or therapeutic product is prohibited in all major jurisdictions. Research chemical distribution is the only legal commercial channel, and that channel is constrained by HS classification (2933.79 in most customs regimes) and by Australia Schedule 4 prescription-only restrictions on consignee documentation.
Procurement & Specification Enquiries
Single-enantiomer (5R) fasoracetam monohydrate form I, research-grade specification, with chiral HPLC and Karl Fischer release data per lot. Quotation turnaround within two business days for standard pack sizes; customs documentation support for AU Schedule 4, EU/UK research-use, and US research-chemical declarations.
Contact the NutraBiotech research-supply team12. Conclusion
Fasoracetam is the most analytically rigorous racetam in active clinical development. Its 38-year trajectory through six corporate sponsors, one Nature Communications placebo-controlled adolescent study with P<0.001 CGI-I and CGI-S endpoints, one ASCEND Phase 2 failure attributable to protocol-design dilution rather than mechanism failure, and two FDA designations (Orphan Drug in October 2024, Rare Pediatric Disease Designation in August 2026) define a development archetype that no other pyrrolidinone compound in the racetam family approaches. For research laboratories, the operational priorities are: (1) confirm single-(5R)-enantiomer identity by InChIKey block (MRVPVSSYSA-N); (2) confirm monohydrate form I by DSC or PXRD; (3) reconcile Karl Fischer water content against the 8.4 % monohydrate stoichiometry for any quantitative protocol; (4) select pack size (10 g, 100 g, 1 kg, 10 kg, 25 kg) against the downstream use case and the transit-lane temperature profile.